双语新闻：已有5人服用小林制药保健品后死亡，93人住院，日本政府：全力回收！
China new net March 29 Japan's Kobayashi Pharmaceutical company said Monday that another person had died after taking a supplement containing monaskoji, bringing the death toll to five, NHK reported.
中新网3月29日电 据日本广播协会(NHK)报道,29日,日本小林制药公司发布消息称,又有1人在服用该公司生产的含红曲成分保健品后死亡,相关死亡人数已增至5人。
Kobayashi Pharmaceutical said that the family of the new victim contacted the company, saying that the victim died after taking health products containing monaskoji ingredients and developing symptoms of suspected kidney disease. This is similar to the cause of death of the previous four victims.
据报道,小林制药称,新增这名死者的家属联系了该公司,称死者是在服用含红曲成分的保健品后出现疑似肾病的症状后死亡。这与此前4名死者的死因类似。
In addition, 93 people are being hospitalized for the same reasons.
此外,还有93人因相同原因正在接受住院治疗。
Japanese Agriculture, Forestry and Fisheries Minister Tetsushi Sakamoto said on the 29th that he had ordered Kobayashi Pharmaceutical to do its best to recall related products to avoid further damage to consumers' health.
日本农林水产大臣坂本哲志在29日表示,已经命令小林制药全力回收相关产品,以避免消费者健康受损问题进一步扩大。
On the 28th, Japanese Prime Minister Fumio Kishida also said on the matter that efforts must be made to find out the cause and consider taking all necessary countermeasures.
28日,日本首相岸田文雄也就此事表示,必须努力查明原因,并考虑采取一切必要的应对措施。
As previously reported, Kobayashi Pharmaceutical decided on March 22 to urgently recall three of the company's health products containing monaskoji ingredients. The company said the problem may have been caused by a previously "unexpected" mildew ingredient in the product, but it is not yet clear what that ingredient is.
据此前报道,小林制药在3月22日决定紧急召回该公司三款含红曲成分的保健品。该公司称,出问题的原因可能是产品混入此前“意想不到”的来自霉菌的成分,但尚未弄清该成分究竟是什么。
Kobayashi Pharmaceutical also sells its monaskoji raw materials to other companies for brewing and food manufacturing in addition to its own health products. The recall of food and condiments made from Kobayashi Pharmaceutical has been expanded to cover all of Japan.
小林制药生产的红曲原料除自家生产保健品外,还出售给其他公司,用于酿酒及食品制造等。目前使用小林制药产红曲原料的食品和调料召回范围已扩大至日本全国。
中新网3月29日电 据日本广播协会(NHK)报道,29日,日本小林制药公司发布消息称,又有1人在服用该公司生产的含红曲成分保健品后死亡,相关死亡人数已增至5人。
Kobayashi Pharmaceutical said that the family of the new victim contacted the company, saying that the victim died after taking health products containing monaskoji ingredients and developing symptoms of suspected kidney disease. This is similar to the cause of death of the previous four victims.
据报道,小林制药称,新增这名死者的家属联系了该公司,称死者是在服用含红曲成分的保健品后出现疑似肾病的症状后死亡。这与此前4名死者的死因类似。
In addition, 93 people are being hospitalized for the same reasons.
此外,还有93人因相同原因正在接受住院治疗。
Japanese Agriculture, Forestry and Fisheries Minister Tetsushi Sakamoto said on the 29th that he had ordered Kobayashi Pharmaceutical to do its best to recall related products to avoid further damage to consumers' health.
日本农林水产大臣坂本哲志在29日表示,已经命令小林制药全力回收相关产品,以避免消费者健康受损问题进一步扩大。
On the 28th, Japanese Prime Minister Fumio Kishida also said on the matter that efforts must be made to find out the cause and consider taking all necessary countermeasures.
28日,日本首相岸田文雄也就此事表示,必须努力查明原因,并考虑采取一切必要的应对措施。
As previously reported, Kobayashi Pharmaceutical decided on March 22 to urgently recall three of the company's health products containing monaskoji ingredients. The company said the problem may have been caused by a previously "unexpected" mildew ingredient in the product, but it is not yet clear what that ingredient is.
据此前报道,小林制药在3月22日决定紧急召回该公司三款含红曲成分的保健品。该公司称,出问题的原因可能是产品混入此前“意想不到”的来自霉菌的成分,但尚未弄清该成分究竟是什么。
Kobayashi Pharmaceutical also sells its monaskoji raw materials to other companies for brewing and food manufacturing in addition to its own health products. The recall of food and condiments made from Kobayashi Pharmaceutical has been expanded to cover all of Japan.
小林制药生产的红曲原料除自家生产保健品外,还出售给其他公司,用于酿酒及食品制造等。目前使用小林制药产红曲原料的食品和调料召回范围已扩大至日本全国。
